Market closedNon-fractional
Apellis Pharmaceuticals/APLS
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
APLS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Waltham, United States
Employees
704
Website
www.apellis.com
APLS Metrics
BasicAdvanced
$4.2B
Market cap
-
P/E ratio
-$3.45
EPS
0.95
Beta
-
Dividend rate
Price and volume
Market cap
$4.2B
Beta
0.95
Financial strength
Current ratio
3.769
Quick ratio
2.814
Long term debt to equity
38.578
Total debt to equity
40.925
Interest coverage (TTM)
-13.93%
Management effectiveness
Return on assets (TTM)
-27.90%
Return on equity (TTM)
-122.94%
Valuation
Price to revenue (TTM)
8.07
Price to book
15.95
Price to tangible book (TTM)
15.95
Price to free cash flow (TTM)
-7.68
Growth
Revenue change (TTM)
394.93%
Earnings per share change (TTM)
-45.05%
3-year revenue growth
27.87%
3-year earnings per share growth
-9.79%
What the Analysts think about APLS
Analyst Ratings
Majority rating from 18 analysts.
APLS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$172M
17.77%
Net income
-$66M
-24.97%
Profit margin
-38.53%
-36.30%
APLS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.02
-$1.17
-$0.73
-$0.54
-
Expected
-$1.32
-$0.86
-$0.69
-$0.47
-$0.32
Surprise
-22.89%
36.77%
6.36%
15.71%
-
APLS News
AllArticlesVideos
![Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU](https://cdn.snapi.dev/images/v1/c/8/press13-2501489.jpg)
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
GlobeNewsWire·6 days ago
![Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference](https://cdn.snapi.dev/images/v1/x/t/conf13-2463200.jpg)
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewsWire·4 weeks ago
![Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress](https://cdn.snapi.dev/images/v1/a/v/press15-2447263.jpg)
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $4.2B as of July 04, 2024.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of July 04, 2024.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell Apellis Pharmaceuticals stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell Apellis Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.